<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255788</url>
  </required_header>
  <id_info>
    <org_study_id>I163</org_study_id>
    <secondary_id>CAN-NCIC-IND163</secondary_id>
    <secondary_id>NOVARTIS-CAN-NCIC-IND163</secondary_id>
    <secondary_id>CDR0000450849</secondary_id>
    <nct_id>NCT00255788</nct_id>
  </id_info>
  <brief_title>Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients With Recurrent/Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying two different schedules of everolimus to&#xD;
      see how well they work in treating patients with recurrent or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of 2 different treatment schedules of everolimus, in terms of&#xD;
           clinical/radiological response and early progression, in patients with recurrent or&#xD;
           metastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to progression and response duration in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Determine the toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Correlate molecular markers of mTOR activity in tumor tissue with objective tumor&#xD;
           response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified&#xD;
      according to presence of visceral metastases (yes vs no) and prior chemotherapy regimens for&#xD;
      recurrent disease (0 vs 1). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral everolimus once daily on days 1-28.&#xD;
&#xD;
        -  Arm II: Patients receive oral everolimus on days 1, 8, 15, and 22. In both arms, courses&#xD;
           repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then periodically&#xD;
      until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2005</start_date>
  <completion_date type="Actual">January 18, 2011</completion_date>
  <primary_completion_date type="Actual">July 22, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate by clinical evaluation every 4 weeks and radiologic reevaluation every 8 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Early progression rate by clinical evaluation every 4 weeks and radiologic reevaluation every 8 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression by clinical evaluation every 4 weeks and radiologic reevaluation every 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration by evaluation 4 weeks after response and then every 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative assessment of response with molecular markers of mTor activity on archival tissue</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optional correlative assessment of response with molecular markers of mTor activity on fresh tissue</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus - 28 days q 4 wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus - days 1, 8, 15 and 22 q 4wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic or recurrent disease&#xD;
&#xD;
               -  Considered incurable&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Two primary breast cancers allowed&#xD;
&#xD;
          -  Paraffin-embedded primary or metastatic tumor sample available&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No upper gastrointestinal condition or other condition that would preclude ability to&#xD;
             take oral medication&#xD;
&#xD;
          -  No other serious medical condition that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or neurologic disorder that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix or bladder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic or recurrent disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 5 days since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy except for low-dose, limited-fraction,&#xD;
             palliative, nonmyelosuppressive radiotherapy, defined as radiotherapy to &lt; 20% of&#xD;
             functioning bone marrow&#xD;
&#xD;
          -  If prior radiotherapy was to sole site of disease, must have subsequent documented&#xD;
             disease progression at that site&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent prophylactic bisphosphonates allowed, if started prior to study entry&#xD;
&#xD;
          -  No concurrent potent inhibitors of cytochrome 3A4, such as erythromycin, diltiazem, or&#xD;
             ketoconazole and similar antifungals&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Ellard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency - Centre for the Southern Interior</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen A. Gelmon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Valley Cancer Centre at British Columbia Cancer Agency</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009 Sep 20;27(27):4536-41. doi: 10.1200/JCO.2008.21.3033. Epub 2009 Aug 17.</citation>
    <PMID>19687332</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

